About this content About Andrew Kessel Andrew is a financial journalist with experience covering public companies in a wide breadth of industries, including tech, medicine, cryptocurrency, mining and retail. In addition to Proactive, he has been published in a Financial Times-owned newsletter covering broker-dealer firms and in the Columbia Misourian newspaper as the lead reporter focused on higher education. He got his start with an internship at Rolling Stone magazine.  Read more About the publisher Pr ...

Shares of Eli Lilly (LLY 3.52%) were jumping 3.3% higher as of 12:07 p.m. ET on Wednesday. This gain looked even better considering that the major market indexes were all slumping.Lilly was able to swim against the market current primarily because of investors' enthusiasm about the prospects for the company's weight-loss drug Zepbound. On Tuesday, BMO analyst Evan Seigerman wrote to clients that Lilly's drug already appeared to be taking market share away from Novo Nordisk's Ozempic and Wegovy. Seigerman st ...

Pharmaceutical company Eli Lilly & Co (LLY 3.56%) is the world's largest drug company. It minted many millionaires on its way to becoming one of the world's largest corporations. The stock has returned an incredible 41,930% over its lifetime, turning a $1,000 investment into $420,000.The stock is up 250% over the past three years alone and is worth over half a trillion dollars today. Did you miss out? That's OK. There's a stock positioned to outperform Eli Lilly, sitting in the pole position of arguably the ...

Eli Lilly (LLY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned +0.7% over the past month versus the Zacks S&P 500 composite's +4% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has gained 4.1% over this period. Now the key question is: Where could the stock be headed in the near term?While media releases or r ...

INDIANAPOLIS, Jan. 2, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will attend the 42nd Annual J.P. Morgan Healthcare Conference, Jan. 8-11, 2024. David A. Ricks, Lilly's chair and CEO, will participate in a fireside chat on Jan. 9 at 5:15 p.m. Eastern time. A live audio webcast will be available on the "Webcasts & Presentations" section of Lilly's Investor website at https://investor.lilly.com/webcasts-and-presentations. A replay of the presentation will be available on this same website for appr ...

Phynart Studio/E+ via Getty Images In my November 2014 Seeking Alpha Article, ARNA Management And Investors Underestimating The Potential Of Belviq And Phentermine Combination, I predicted: …The obesity drugs which will be used in the future to treat obesity will have profound impacts on the economy. At some point the definition of an advanced economy might be one that spends more money on anti-obesity medication than on food…. Today, in regard to spending more money on anti-obesity medication than on food, ...

Eli Lilly (LLY 0.36%) has been one of the hottest healthcare stocks to own in recent years. The company is now the most valuable healthcare company in the world, with a valuation of around $550 billion. So, investors may be wondering whether the stock has peaked, and perhaps it's time to hold off on buying it or cashing out their investments in the healthcare stock.But that could be a mistake. Eli Lilly has a lot of growth left in its business. And while the hype has largely been around its weight-loss trea ...

2023 was a great year to have money working for you in the U.S. stock market. The S&P 500 index rose about 25%, and some of its components did a whole lot better.Seasoned investors like owning shares of well-established pharmaceutical companies like Eli Lilly (LLY 0.36%) because patent-protected exclusivity for their products makes them reliably profitable. They aren't, however, generally known for putting up huge gains like Eli Lilly did last year.The big pharma company helped lift the benchmark S&P 500 in ...

INDIANAPOLIS, Dec. 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the successful completion of its acquisition of POINT Biopharma Global Inc. (NASDAQ: PNT), a radiopharmaceutical company with a pipeline of clinical and preclinical-stage radioligand therapies in development for the treatment of cancer. "Next generation radioligand therapies hold great promise for delivering meaningful advances against a range of cancers and we are excited to enter this space through the addition o ...

Biotech giant Eli Lilly (LLY -0.43%) has been firing on all cylinders this year. The company's popularity rose along with weight-loss medicine, an area in which it's one of the leaders. Its financial results have been solid, and its stock performance has crushed that of the broader market.Some might wonder whether they've missed the boat with this drugmaker. Can Eli Lilly pull off a similar performance in 2024?There will be more key approvalsEli Lilly scored several approvals this year, including one for Om ...